Who Paid My Doc
Michael Nolen
Thoracic Surgery (Cardiothoracic Vascular Surgery) Little Rock, AR Medical Doctor
NPI 1164515318 CMS profile 143356
7 Shackleford West Blvd, Suite 402, Little Rock, AR 72211
General payments
$14,590
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$6,210
Through program year 2025, Michael Nolen of Little Rock, AR is reported in the CMS Open Payments database as having received $14,590 across 204 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,210 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 74th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,611 | 27 | |
| 2024 | General | $4,075 | 48 | |
| 2023 | General | $1,269 | 30 | |
| 2022 | General | $2,117 | 39 | |
| 2021 | General | $1,374 | 18 | |
| 2020 | General | $1,336 | 13 | |
| 2019 | General | $2,809 | 29 |
Beside peers
- Michael Nolen
- Thoracic Surgery (Cardiothoracic Vascular Surgery) median
- Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
- National median
In program year 2025, general payments to Michael Nolen were reported at $1,611. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.
Show as a table
| Year | Michael Nolen | Thoracic Surgery (Cardiothoracic Vascular Surgery) median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,809 | $886 | $178–$3,167 | $163 |
| 2020 | $1,336 | $341 | $108–$1,605 | $114 |
| 2021 | $1,374 | $453 | $125–$1,886 | $132 |
| 2022 | $2,117 | $695 | $180–$2,566 | $149 |
| 2023 | $1,269 | $745 | $205–$2,662 | $160 |
| 2024 | $4,075 | $799 | $214–$2,967 | $164 |
| 2025 | $1,611 | $791 | $208–$3,074 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
524
Drug cost
$12,816
Branded share of claims
3.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 19 | $11,901 | |
| Atorvastatin Calcium | Generic | 14 | $220 | |
| Amlodipine Besylate | Generic | 14 | $121 | |
| Potassium Chloride | Generic | 16 | $115 | |
| Allopurinol | Generic | 188 | $112 | |
| Famotidine | Generic | 186 | $110 | |
| Metoprolol Tartrate | Generic | 34 | $98 | |
| Hydralazine Hcl | Generic | 14 | $62 | |
| Furosemide | Generic | 25 | $56 | |
| Hydrochlorothiazide | Generic | 14 | $22 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 411 Part D prescribers listed as Cardiac Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 60 billing codesPaid by Medicare
$322,613
Medicare patients
266
Services billed
684
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 75% | |
| Atrial fibrillation | 53% | |
| Arthritis | 46% | |
| Heart failure | 42% | |
| Diabetes | 39% | |
| Chronic kidney disease | 33% | |
| COPD | 29% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
204 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in Arkansas
Bassam Shukrallah
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Little Rock, AR
James Spann
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Rogers, AR
Jay Bhama
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Jonesboro, AR
Pouya Hemmati
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Little Rock, AR
Katy Marino
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Little Rock, AR
Edgar Chauvin
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Rodgers, AR
Related records
Thoracic Surgery (Cardiothoracic Vascular Surgery) in Arkansas
Practitioners in the same specialty and state, ranked by reported value.
All Thoracic Surgery (Cardiothoracic Vascular Surgery)
Everyone recorded under this specialty, nationwide.
Doctors in Arkansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.